Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2188239rdf:typepubmed:Citationlld:pubmed
pubmed-article:2188239lifeskim:mentionsumls-concept:C0036262lld:lifeskim
pubmed-article:2188239lifeskim:mentionsumls-concept:C0008059lld:lifeskim
pubmed-article:2188239lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:2188239lifeskim:mentionsumls-concept:C0358202lld:lifeskim
pubmed-article:2188239lifeskim:mentionsumls-concept:C0975958lld:lifeskim
pubmed-article:2188239lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:2188239lifeskim:mentionsumls-concept:C0699631lld:lifeskim
pubmed-article:2188239lifeskim:mentionsumls-concept:C0720177lld:lifeskim
pubmed-article:2188239pubmed:issue1lld:pubmed
pubmed-article:2188239pubmed:dateCreated1990-6-27lld:pubmed
pubmed-article:2188239pubmed:abstractTextPermethrin 5% cream (Elimite) was approved as a treatment for scabies by the U.S. Food and Drug Administration in September 1989. In a double-blinded, randomized study, it was compared with crotamiton 10% cream (Eurax) for the treatment of scabies in children 2 months to 5 years of age. Two weeks after a single overnight treatment, 14 (30%) of 47 children were cured with permethrin 5% cream, in contrast to only 6 of 47 (13%) of subjects treated with Eurax. Four weeks after treatment the figures were 89% and 60% cured for the two agents, respectively. In 10 of the 19 patients whose treatment failed, the condition became worse after therapy. The difference in efficacy in favor of permethrin was significant (P = 0.002). That agent also demonstrated greater effectiveness in reducing pruritus and secondary bacterial infections. Elimite offers a safe, efficacious, and cosmetically elegant alternative to Eurax in the treatment of scabies in children.lld:pubmed
pubmed-article:2188239pubmed:languageenglld:pubmed
pubmed-article:2188239pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2188239pubmed:citationSubsetIMlld:pubmed
pubmed-article:2188239pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2188239pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2188239pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2188239pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2188239pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2188239pubmed:statusMEDLINElld:pubmed
pubmed-article:2188239pubmed:monthMarlld:pubmed
pubmed-article:2188239pubmed:issn0736-8046lld:pubmed
pubmed-article:2188239pubmed:authorpubmed-author:SanchezRRlld:pubmed
pubmed-article:2188239pubmed:authorpubmed-author:TaplinDDlld:pubmed
pubmed-article:2188239pubmed:authorpubmed-author:MeinkingT LTLlld:pubmed
pubmed-article:2188239pubmed:authorpubmed-author:ChenJ AJAlld:pubmed
pubmed-article:2188239pubmed:issnTypePrintlld:pubmed
pubmed-article:2188239pubmed:volume7lld:pubmed
pubmed-article:2188239pubmed:ownerNLMlld:pubmed
pubmed-article:2188239pubmed:authorsCompleteYlld:pubmed
pubmed-article:2188239pubmed:pagination67-73lld:pubmed
pubmed-article:2188239pubmed:dateRevised2009-3-3lld:pubmed
pubmed-article:2188239pubmed:meshHeadingpubmed-meshheading:2188239-...lld:pubmed
pubmed-article:2188239pubmed:meshHeadingpubmed-meshheading:2188239-...lld:pubmed
pubmed-article:2188239pubmed:meshHeadingpubmed-meshheading:2188239-...lld:pubmed
pubmed-article:2188239pubmed:meshHeadingpubmed-meshheading:2188239-...lld:pubmed
pubmed-article:2188239pubmed:meshHeadingpubmed-meshheading:2188239-...lld:pubmed
pubmed-article:2188239pubmed:meshHeadingpubmed-meshheading:2188239-...lld:pubmed
pubmed-article:2188239pubmed:meshHeadingpubmed-meshheading:2188239-...lld:pubmed
pubmed-article:2188239pubmed:meshHeadingpubmed-meshheading:2188239-...lld:pubmed
pubmed-article:2188239pubmed:meshHeadingpubmed-meshheading:2188239-...lld:pubmed
pubmed-article:2188239pubmed:meshHeadingpubmed-meshheading:2188239-...lld:pubmed
pubmed-article:2188239pubmed:meshHeadingpubmed-meshheading:2188239-...lld:pubmed
pubmed-article:2188239pubmed:meshHeadingpubmed-meshheading:2188239-...lld:pubmed
pubmed-article:2188239pubmed:meshHeadingpubmed-meshheading:2188239-...lld:pubmed
pubmed-article:2188239pubmed:meshHeadingpubmed-meshheading:2188239-...lld:pubmed
pubmed-article:2188239pubmed:year1990lld:pubmed
pubmed-article:2188239pubmed:articleTitleComparison of crotamiton 10% cream (Eurax) and permethrin 5% cream (Elimite) for the treatment of scabies in children.lld:pubmed
pubmed-article:2188239pubmed:affiliationDepartment of Dermatology and Cutaneous Surgery, University of Miami School of Medicine, FL 33101.lld:pubmed
pubmed-article:2188239pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2188239pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:2188239pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:2188239pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:2188239pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2188239lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2188239lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2188239lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2188239lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2188239lld:pubmed